Medtronic reports registry results as Medtronic stock gains 3.36 percent

Published on 10/23/2026 at 09:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic posted 100.00 percent acute success in 1,160 patients on October 22, 2026. Medtronic stock costs EUR 85.67, 3.36 percent above its EUR 82.88 Xetra close.

Registry evidence and scheduled dates

Medtronic presented results from 1,050 atrial fibrillation patients on October 22, 2026.
Fiscal first-quarter revenue reached USD 9.76 billion on September 1, 2026.
Medtronic stock trades at EUR 85.67 at 9:15 a.m. CEST at Lang & Schwarz on October 23, 2026, 3.36 percent above the Xetra close of October 22, 2026.

Aquarellmalerei der Dubliner Skyline entlang des Flusses Liffey in warmen Farben — Medtronic plc (ISIN IE00BTN1Y115) Aquarellbild zeigt die Skyline von Dublin entlang des Flusses Liffey stimmungsvoll, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 85.67 at Lang & Schwarz on October 23, 2026, at 9:15 a.m. CEST, up 3.36 percent versus the Xetra close of October 22, 2026, at EUR 82.88. The medical technology company announced new real-world registry results on October 22, 2026, as Medtronic presented data on its Sphere-9 catheter and PulseSelect system at the Asia Pacific Heart Rhythm Society meeting.

Registry results add clinical evidence

The APEX registry included 1,050 atrial fibrillation patients treated across 28 global sites, with a major complication rate of 1.10 percent. The REAL PULSE registry covered 1,160 patients at 38 sites and reported a 100.00 percent acute success rate alongside a 0.09 percent acute major complication rate, according to Medtronic.

What does the outlook imply?

The latest operating backdrop remains stronger than the prior-year comparison. Medtronic reported USD 9.76 billion of fiscal first-quarter 2027 revenue on September 1, 2026, up 13.70 percent year over year, while adjusted earnings per share reached USD 1.45 against a USD 1.39 consensus estimate, as Markets Insider reported. The company set second-quarter fiscal 2027 adjusted earnings-per-share guidance at USD 1.32 to USD 1.34, according to MarketBeat.

Three dates frame the story

On September 1, 2026, Medtronic reported fiscal first-quarter revenue of USD 9.76 billion. On October 12, 2026, BTIG Research lowered its price target from USD 100.00 to USD 99.00 while keeping a Buy rating, as MarketBeat reported. On October 22, 2026, the Sphere-9 and PulseSelect registries supplied the latest operating evidence, including 87.00 percent acute success among 46 ventricular tachycardia patients, according to Medtronic.

Upcoming dates set the next test

Medtronic is scheduled to announce second-quarter fiscal 2027 results on November 17, 2026, before the market opens, according to Yahoo Finance. The investor day is due on December 10 and December 11, 2026, according to Boardroom Alpha.

Clinical evidence meets valuation

The market reaction places the registry update alongside a broad earnings recovery, but the analyst picture is more measured. Piper Sandler reiterated a Hold rating and set a USD 85.00 target on October 22, 2026, according to Markets Insider. Medtronic's primary listing is on the NYSE, where the stock was last quoted at USD 96.59 on October 22, 2026, while its market capitalization was USD 123.6 billion and its 52-week range was USD 73.31 to USD 106.33.

Medtronic was trading at EUR 85.67 at Lang & Schwarz on October 23, 2026, at 9:15 a.m. CEST, 3.36 percent above the Xetra close of October 22, 2026, at EUR 82.88. The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.